{"organizations": ["Intrexon Corp"], "uuid": "a3f0679ca3cb7d718d2a25a01e67191b1461d15e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/InVitroDiagnosticsFinancing", "section_title": "In Vitro Diagnostics Financing from Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530656?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522In%2520Vitro%2520Diagnostics%2522)%2520%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "", "title": "Intrexon Corp nets $218.5mm in follow-on offering", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Intrexon Corp nets $218.5mm in follow-on offering", "spam_score": 0.0, "site_type": "news", "published": "2015-09-01T02:40:00.000+03:00", "replies_count": 0, "uuid": "a3f0679ca3cb7d718d2a25a01e67191b1461d15e"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530656?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522In%2520Vitro%2520Diagnostics%2522)%2520%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Intrexon Corp nets $218.5mm in follow-on offering", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Intrexon Corp nets $218.5mm in follow-on offering Deal Date: Aug-01-2015 / Deal # 201530656 Executive Summary \nIntrexon Corp. (synthetic biology for drug discovery) netted $218.5mm in a follow-on equity offering of 5.6mm shares (including the over-allotment) at $41. The company bought Oxitec Ltd. and Okanagan Specialty Fruits in August 2015 and ActoGeniX NV in February 2015. Intrexon will use proceeds from the offering in part for acquisitions and investments, including funding a portion of the Oxitec buy.", "external_links": [], "published": "2015-09-01T02:40:00.000+03:00", "crawled": "2015-09-01T16:58:49.271+03:00", "highlightTitle": ""}